Boyds join clinical programme team to develop orphan drug Trappsol Cyclo
Posted: 11 May 2015 |
Boyds has joined CTD Holdings’ Clinical Programme Team along with Aptus Clinical and KJC Statistics to develop orphan drug Trappsol Cyclo with Accenture…
Boyds has joined CTD Holdings’ International Clinical Programme Team along with Aptus Clinical and KJC Statistics to develop orphan drug Trappsol® Cyclo™ with Accenture.
CTD Holdings is a family of biotechnology companies that develop cyclodextrin-based treatments and other products. Together, clinical research specialists Accenture, Aptus, Boyds and KJC bring strong international experience to CTDs orphan drug development programme.
Trappsol Cyclo is used for the treatment of Niemann-Pick Type C (NP-C). NP-C is a rare genetic disease where fatty molecules slowly build up in the body to levels that can eventually cause serious problems. NP-C affects infants, children and adults and affects about one in every 120,000 births worldwide.
The company holds orphan designation for Trappsol Cyclo in Europe and is obtaining orphan drug designation in the US. It is currently being used as an investigational new drug on a compassionate use or named patient basis in Europe, Brazil and the U.S.
Trappsol Cyclo is being developed for a clear, unmet medical need
Professor Alan Boyd, CEO and Founder of Boyds said, “Together our group has extensive experience in the development and commercialisation of orphan drugs. We are delighted to bring this experience to CTD’s International Clinical Programme for Trappsol Cyclo, which is being developed for a clear, unmet medical need.”
President and CEO of CTD Holdings, Dr Jeffrey Tate, added, “We have assembled a powerful team for our International Clinical Programme. The addition of Aptus, Boyds and KJC reflects our commitment to completing clinical trials quickly and making Trappsol Cyclo available to Niemann-Pick Type C patients around the world.”
All parties have signed contracts and the project is now underway.
